- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03880227
Improving Visual Attention in Schizophrenia
Improving Visual Attention to Social Stimuli in Individuals With Schizophrenia
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Individuals with schizophrenia tend to display abnormal visual attention when performing visual tasks, typically spending less time on salient features of the stimuli (e.g. core facial features or body movement in social tasks), and instead focusing on idiosyncratic features of an image or video. Poor visual attention in schizophrenia has been directly linked to poorer social cognitive performance (e.g. recognizing emotional expressions or social cues) which can impact an individual's day to day functioning.
Transcranial Direct Current Stimulation (tDCS) is a form of noninvasive neurostimulation which has been proposed as a therapeutic procedure in numerous psychiatric disorders. TDCS in schizophrenia has been demonstrated to improve a wide range of cognitive processes, and in healthy adults, tDCS has been demonstrated to improve aspects of social cognition. TDCS thus appears to be a promising therapeutic technique that may be useful for improving visual attention in patients with schizophrenia, and potentially impact social cognitive performance via an underlying mechanism tying the two. This study will compare visual performance in individuals with schizophrenia across two conditions: active anodal tDCS and sham tDCS, while also comparing between brain stimulation sites: rTPJ and dmPFC.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Texas
-
Richardson, Texas, États-Unis, 75080
- The University of Texas at Dallas
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- DSM-IV-TR or DSM-5 diagnosis of schizophrenia or schizoaffective disorder and clinically stable (i.e. no hospitalizations) for at least 8 weeks prior to informed consent and be on a stable medication regimen for at least 6 weeks with no dose changes for a minimum of 2 weeks prior to informed consent.
Exclusion Criteria:
- The presence or history of a pervasive developmental disorder or mental retardation as defined by a premorbid IQ < 70
- Presence or history of medical or neurological disorders in which neural stimulation would be contraindicated (e.g. presence of epilepsy or history of seizures)
- Presence of sensory limitations, including visual or hearing impairments that interfere with assessment
- History of electroconvulsive therapy
- Not proficient in English
- Presence of substance abuse in the past one month or dependence not in remission in the past six months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Anodal followed by sham stimulation tDCS to rTPJ
cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing.
After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
|
active anodal tDCS with behavioral tasks to assess visual attention
sham tDCS with behavioral tasks to assess visual attention
|
Comparateur actif: Anodal followed by sham stimulation tDCS to dmPFC
cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing.
After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
|
active anodal tDCS with behavioral tasks to assess visual attention
sham tDCS with behavioral tasks to assess visual attention
|
Expérimental: Sham followed by anodal stimulation tDCS to rTPJ
cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing.
After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
|
active anodal tDCS with behavioral tasks to assess visual attention
sham tDCS with behavioral tasks to assess visual attention
|
Comparateur actif: Sham followed by anodal stimulation tDCS to dmPFC
cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing.
After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
|
active anodal tDCS with behavioral tasks to assess visual attention
sham tDCS with behavioral tasks to assess visual attention
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Visual Attention to Static Faces
Délai: Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Visual attention measured via eye-tracking (percentage of time attending to investigator designated AOIs) when viewing static, emotional faces (stimuli: Emotion Recognition - 40).
AOIs for static faces will be defined as core facial features (i.e.
eyes, nose, mouth).
|
Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Visual Attention to Dynamic Actor
Délai: Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Visual attention measured via eye-tracking(percentage of time attending to investigator designated AOIs) when viewing videos of a single actor (stimuli: Bell Lysaker Emotion Recognition Task).
AOIs for this task will be defined as core facial features (i.e.
eyes, nose, and mouth).
|
Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Visual Attention to Dynamic Social Scenes
Délai: Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Visual attention measured via eye-tracking (percentage of time attending to investigator designated AOIs) when viewing videos of two or more actors in a scene (stimuli: The Awareness of Social Inference Task Part 3, Version A).
AOIs for this task will be defined as salient social and contextual stimuli (e.g.
social stimuli are faces of actors, while contextually salient stimuli include items actors are talking about, such as a plate full of food or an empty wallet).
|
Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Fixation Stabilization
Délai: Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Stabilization of visual fixation on fixation circle positioned in middle of screen.
Participants will be placed in front of an eyetracking device and asked to keep their eyes focused on a circle in the middle of the screen.
Stabilization will be measured via eye-tracking as the deviation from a single point on screen, calculated by assessing the sum of squares of both the x and y axis (output from eyetracking device).
Higher number indicates more movement, and thus less stabilization.
|
Assessment will be completed 30 minutes after completion of the active/sham stimulation
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Hans S Klein, MS, University of Texas at Dallas
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 19-58
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Active anodal tDCS
-
Universidad Complutense de MadridInconnuePerformance athlétiqueEspagne
-
Maastricht University Medical CenterB. Braun/Aesculap SpineComplétéDéplacement du disque intervertébral | DiscectomiePays-Bas
-
Hospital de Clinicas de Porto AlegreActif, ne recrute pas
-
Children's Hospital Medical Center, CincinnatiRésilié
-
Riphah International UniversityComplétéAccident vasculaire cérébralPakistan
-
Federal University of ParaíbaUniversidade Federal do Rio Grande do NorteInconnueAccident vasculaire cérébral | Déficience cognitive | Infarctus cérébralBrésil
-
José Casaña GranellUniversity of Alcalá. Physiotherapy in Women's Health (FPSM) Research Group...ComplétéIncontinence urinaire | Troubles du plancher pelvien | Faiblesse des muscles du plancher pelvien | Incontinence urinaire, StressEspagne
-
Istituto Auxologico ItalianoComplétéAccident vasculaire cérébral | Hémianopsie, homonymeItalie
-
Medical University of South CarolinaComplétéAccident vasculaire cérébralÉtats-Unis